PROGRAMME OF LIVE SESSIONS: CET timing

The programme below will take place live. This time schedule corresponds to CET timing. Click here to adapt the CET time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting

ESH EUROPEAN SCHOOL OF HAEMATOLOGY

E-Conference:
3rd How to Diagnose and Treat
Acute Leukaemias
March 10-13, 2022
Chairs : Hervé Dombret, Gert Ossenkoppele, Jorge Sierra, Wendy Stock

Thursday, March 10, 2022

14:00-14:05 **Welcome : Hervé Dombret, Gert Ossenkoppele, Jorge Sierra, Wendy Stock**

14:05-14:50 **Keynote lecture**
Chair: Gert Ossenkoppele (Amsterdam)

14:05-14:10	Introduction	Gert Ossenkoppele (Amsterdam)
14:10-14:40	Will standard AML cytogenetics become prehistoric?	David Spencer (St Louis)
14:40-14:50	*Discussion*	

SESSION I – Diagnosis and rare diseases
Chairs: Paresh Vyas (Oxford), Wendy Stock (Chicago)

14:50-14:55	Introduction	Paresh Vyas (Oxford), Wendy Stock (Chicago)
14:55-15:15	Case-based lecture: Do we need more AML genes than the ELN-2017 ones?	Elli Papaemmanuil (New York)
15:15-15:35	Case-based lecture: TP53-mutated AML	Lars Bullinger (Berlin)

15:35-15:55 Case-based lecture: Marielle Wondergem (Amsterdam)
MPAL with t(9;22)

15:55-16:05 Interactive case: Emily Curran (Cincinnati)
Ph-like ALL

16:05-16:25 Case-based lecture: Wendy Stock (Chicago)
Early T-cell precursor ALL

16:25-16:30 Brief oral communication
Improved copy number aberration-based genetic classification refines risk assessment in pediatric B-Cell acute lymphoblastic leukemia — *Gábor Bedics (Budapest)*

16:30-17:00 Panel discussion

17:00-17:10 Coffee break

SESSION II – Measurable Residual Disease (MRD)
Chairs: Sylvie Freeman (Birmingham), Gert Ossenkoppele (Amsterdam)

17:10-17:15 Introduction — Sylvie Freeman (Birmingham), Gert Ossenkoppele (Amsterdam)

17:15-17:35 Case-based lecture: Sylvie Freeman (Birmingham)
Methods for MRD assessment in AML

17:35-17:55 Case-based lecture: Jan Trka (Prague)
Methods for MRD assessment in ALL

17:55-18:05 Interactive case: Adriano Venditti (Rome)
MRD negativity as therapeutic goal in AML

18:05-18:15 Interactive case: Nicolas Boissel (Paris)
MRD undetectable as therapeutic goal in ALL

18:15-18:25 Interactive case: Farhad Ravandi (Houston)
Evaluation of response in non-intensively treated AML patients

18:25-18:30 Brief oral communication
Pre-leukemic HSPCs with a DNMT3A mutation are positively selected by fatty bone marrow — *Nathali Kaushansky (Rehovot)*

18:30-19:00 Panel discussion

19:10-20:10 ***Mentored Poster Walk***
Leaders: Sylvie Freeman (Birmingham), Adriano Venditti (Rome)

Friday, March 11, 2022

13:00-14:00 **SATELLITE SYMPOSIUM**
Maintaining Remission in Patients with AML: Challenges and Opportunities
Chair: Gail Roboz (New York)
Speakers: Uma Borate (Portland), Michael Pfeilstöcker (Vienna)

This symposium is organised and sponsored by Bristol-Myers Squibb Company

SESSION III – Leukaemia treatment dilemmas
Chairs: Herve Dombret (Paris), Richard Stone (Boston)

14:10-14:15	Introduction	Herve Dombret (Paris), Richard Stone (Boston)
14:15-14:25	Interactive case: How to decide fitness for intensive AML therapy?	Lionel Adès (Paris)
14:25-14:45	Case-based Lecture: Non-intensive treatment for AML: To target or not to target?	Paresh Vyas (Oxford)
14:45-15:05	Case-based lecture: Who should receive a RIC transplant?	Charles Craddock (Birmingham)
15:05-15:25	Case-based lecture: P53 mutant leukaemia: Is there a good treatment approach?	David Sallman (Tampa)
15:25-15:35	Interactive case: What is refractory AML and what to do?	Richard Stone (Boston)
15:35-15:40	Brief oral communication *Prediction of major complications and early death during intensive therapy for AML*	*Guillermo Ramil (Barcelona)*
15:40-16:10	*Panel discussion*	
16:10-16:20	***Coffee break***	
16:20-17:15	**DEBATE 1 – Intensive chemotherapy for older fit patients** **Chair:** Fahrad Ravandi (Houston)	
16:20-16:25	Introduction	Fahrad Ravandi (Houston)
Audience votes PRO or CON		
16:25-16:40	PRO: The reasons to favour standard intensive chemotherapy	Christoph Röllig (Dresden)
16:40-16:55	CON: The reasons to favour venetoclax-azacitidine	Courtney DiNardo (Houston)
16:55-17:15	*Discussion*	
Audience votes again PRO or CON		

17:15-18:10 ROUNDTABLE 1 – MRD level before transplant
Chair: Charles Craddock (Birmingham)

17:15-17:20	Introduction	Charles Craddock (Birmingham)
17:20-17:35	The value of pre-transplant MRD in AML and how to use it?	Roland Walter (Seattle)
17:35-17:50	The value of pre-transplant MRD in ALL and how to use it?	Sebastian Giebel (Gliwice)
17:50-18:10	*Discussion*	

18:20-19:20 3 Simultaneous Meet the Expert sessions

1.	FLT3inhibition and other targeted treatment	Jordi Esteve (Barcelona), Richard Stone (Boston)
2.	Molecular heterogeneity of AML	Lars Bullinger (Berlin), Elli Papaemmanuil (New York)
3.	Less intensive therapy in AML	Lionel Adès (Paris), Gail Roboz (New York)

Saturday, March 12, 2022

10:50-11:50 SATELLITE SYMPOSIUM
High-risk AML in 2022: what is the go-to strategy?
Chair: Gert Ossenkoppele (Amsterdam)
Speakers: Lars Bullinger (Berlin), Gert Ossenkoppele (Amsterdam), Thomas Schröder (Essen)

This symposium is organised and funded by Jazz Pharmaceuticals

SESSION IV – Leukaemia treatment challenges
Chairs : Gail Roboz (New York), Gert Ossenkoppele (Amsterdam)

12:00-12:05	Introduction	Gail Roboz (New York), Gert Ossenkoppele (Amsterdam)
12:05-12:15	Interactive case: The future of menin inhibitors	Eunice Wang (Buffalo)
12:15-12:35	Case-based lecture: How to treat FLT3 mutant AML at diagnosis and at relapse?	Alexander Perl (Philadelphia)
12:35-12:55	Case-based lecture: Maintenance therapy without transplant	Gail Roboz (New York)
12:55-13:15	Case-based lecture: Innovative treatment for relapsed AML	Jorge Sierra (Barcelona)
13:15-13:25	Interactive case: The future of IDH inhibitors	Eytan Stein (New York)

13:25-13:30 Brief oral communication

AGILE: A global, randomized, double-blind, phase 3 study of Ivosidenib + Azacitidine versus Placebo + Azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation — *Christian Récher (Toulouse)*

13:30-14:00 Panel discussion

14:00-15:25 Lunch

14:15-15:15 SATELLITE SYMPOSIUM

Improving Outcomes in Relapsed/Refractory Paediatric and Young Adult ALL Patients with CAR-T Therapy

Chair: Gergely Kriván (Budapest)

Speakers: Sara Ghorashian (London), Elad Jacoby (Ramat Gan)

This symposium is organized and funded by Novartis

15:25-16:35 ROUNDTABLE 2 – Ph-positive ALL

Chair: Nicola Gökbuget (Frankfurt)

15:25-15:30	Introduction	Nicola Gökbuget (Frankfurt)
15:30-15:45	Initial treatment for Ph+ ALL chemo free or not	Yves Chalandon (Geneva)
15:45-16:00	Which patients with Ph+ ALL should be transplanted?	Sabina Chiaretti (Rome)
16:00-16:15	Post-remission and maintenance treatment for non-transplanted patients	Nicholas Short (Houston)
16:15-16:35	*Discussion*	

16:35-17:30 DEBATE 2 – CAR T-cell for ALL patients

Chair: Hervé Dombret (Paris)

16:35-16:40	Introduction	Hervé Dombret (Paris)
Audience votes		
16:40-16:55	CAR T-cell is a curative ALL therapy	Shannon Maude (Philadelphia)
16:55-17:10	CAR T-cell as a bridge to transplant	Claire Roddie (London)
17:10-17:30	*Discussion*	

Audience votes again

17:30-17:40 Coffee break

SESSION V- Immune therapies to treat leukaemia patients
Chair: John Dipersio (Saint-Louis), Adriano Venditti (Rome)

17:40-17:45	Introduction	John Dipersio (Saint-Louis), Adriano Venditti (Rome)
17:45-17:55	Interactive case: Severe complications of immune therapies	Hermann Einsele (Würzburg)
17:55-18:15	Case-based lecture: Inotuzumab versus blinatumomab in R/R ALL patients	Nicola Gökbuget (Frankfurt)
18:15-18:35	Case-based lecture: New developments in CAR-T and NK cell therapy	Fabio Ciceri (Milan)
18:35-18:55	Case-based lecture: Antibody-based therapies for AML patients	John DiPersio (Saint-Louis)
18:55-19:05	Interactive case: Combining checkpoints inhibitors	Patrick A. Brown (Baltimore)
19:05-19:10	Brief oral communication *Efficacy and safety of Sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukaemia (AML): Final Analysis from a Phase Ib Study*	*Andrew M. Brunner (Boston)*
19:10-19:40	*Panel discussion*	

19:50-20:50 3 Simultaneous Meet the Expert Sessions

1.	Use of asparaginase in adults with ALL	Nicola Gökbuget (Frankfurt), Josep Ribera (Barcelona)
2.	Treatment of adolescent and young adults with ALL	Rob Pieters (Utrecht) Wendy Stock (Chicago)
3.	Treatment of relapsed AML	Charles Craddock (Birmingham), Christian Récher (Toulouse)

Sunday, March 13, 2022

09:15-10:15 SATELLITE SYMPOSIUM
MRD monitoring in ALL Patients: Recent Developments and Real-World Experience
Speakers: Lori Muffly (Stanford), Bijal Shah (Tampa)

This symposium is organised and funded by Adaptive Biotechnologies

10:15-10:25 Coffee break

SESSION VI – Haematopoietic stem cell transplantation
Chair: Jorge Sierra (Barcelona), Robert Zeiser (Freiburg)

10:25-10:30	Introduction	Jorge Sierra (Barcelona), Robert Zeiser (Freiburg)
10:30-10:40	Interactive case: Is there a place for transplantation in AML patients not intensively treated frontline?	Pierre Fenaux (Paris)
10:40-11:00	Case-based lecture: Post-transplant maintenance therapies	Rita Assi (Beirut)
11:00-11:20	Case-based lecture: Treating post-transplant recurrences with immune interventions	Annoek E. C. Broers (Rotterdam)
11:20-11:40	Case-based lecture: Treatment of Steroid - Refractory GVHD	Robert Zeiser (Freiburg)
11:40-12:00	Case-based lecture: Which AML patients should be transplanted in CR1	Raphaël Itzykson (Paris)
12:00-12:05	<u>Brief oral communication</u> A phase Ib study exploring MDM2 inhibitor Siremadlin (HDM201) in combination with Venetoclax in patients with acute myeloid leukemia or very high/high-risk myelodysplastic syndrome	*Kimmo Porkka (Helsinki)*
12:05-12:35	*Panel discussion*	
12:35-12:40	***Closing remarks***	

MEETING CLOSURE